Showing results (141-150 of 5,042) with videos related to

Sort By:
Pageof 505
Multiple Sclerosis and Related Disorders|January 5, 2023
Criterion validity of muscle strain analyses of skeletal muscle function in patients with multiple sclerosisMaria Thorning, Kate Lykke Lambertsen, Cecilie Dollerup Skov, et al.
Multiple Sclerosis and Related Disorders|January 5, 2023
Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trialAsiye Tuba Ozdogar, Ozge Ertekin, Turhan Kahraman, et al.
Multiple Sclerosis and Related Disorders|May 1, 2020
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)Francesco Patti, Clara Grazia Chisari, Emanuele D'Amico, et al.
Multiple Sclerosis and Related Disorders|April 21, 2015
Economic costs associated with an MS relapseK O'Connell, S B Kelly, E Fogarty, et al.
Multiple Sclerosis and Related Disorders|April 21, 2015
Vitamin D status and age of onset of demyelinating diseaseJ Nicholas Brenton, Scott Koenig, Myla D Goldman
Multiple Sclerosis and Related Disorders|April 21, 2015
Natalizumab reduces relapse clinical severity and improves relapse recovery in MSFred D Lublin, Gary Cutter, Gavin Giovannoni, et al.
Multiple Sclerosis and Related Disorders|April 25, 2020
Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in a Colombian PopulationAndrea N Alarcón, Oscar D Ayala, Juan R García, et al.
Multiple Sclerosis and Related Disorders|April 25, 2020
Validation of the Neuronorma battery for neuropsychological assessment in multiple sclerosisJordi A Matías-Guiu, Gonzalo Sánchez-Benavides, Neus Rivera-Àvila, et al.
Multiple Sclerosis and Related Disorders|May 15, 2020
Cryptococcal meningitis in a patient with multiple sclerosis on dimethyl fumarate treatment: A case reportH H Workel, M J H M Wolfhagen, J W Bouwhuis, et al.
Multiple Sclerosis and Related Disorders|May 30, 2020
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximabMichael Auer, Gabriel Bsteh, Harald Hegen, et al.
Pageof 505